Information Journal Paper
APA:
Copy. (2021). Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. LANCET, 397(10275), 671-681. SID. https://sid.ir/paper/1013021/en
Vancouver:
Copy. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. LANCET[Internet]. 2021;397(10275):671-681. Available from: https://sid.ir/paper/1013021/en
IEEE:
Copy, “Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia,” LANCET, vol. 397, no. 10275, pp. 671–681, 2021, [Online]. Available: https://sid.ir/paper/1013021/en